

# Pfenex to Present at the Morgan Stanley Healthcare Conference

SAN DIEGO, Sept. 11, 2015 [/PRNewswire/](#) -- Pfenex Inc. (NYSE MKT: PFNX) announced today that Bertrand C. Liang, chief executive officer of Pfenex will be presenting at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt New York, 109 East 42<sup>nd</sup> Street, New York on September 18 at 2:10 pm ET. To access the live webcast link, please log on to [www.pfenex.com](http://www.pfenex.com).

Pfenex has used, and intends to continue to use, its Investor Relations website (<http://pfenex.investorroom.com>), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit (<http://pfenex.investorroom.com>).

## About Pfenex Inc.


Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its *Pfenex* Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.

Logo - <http://photos.prnewswire.com/prnh/20140715/127348>

SOURCE Pfenex Inc.

For further information: Paul Wagner, Ph.D., Chief Financial Officer, (858) 352-4333, [pwagner@pfenex.com](mailto:pwagner@pfenex.com)

---

Additional assets available online:  [Photos \(1\)](#)